Protalix BioTherapeutics
PLX
35 hedge funds and large institutions have $4.46M invested in Protalix BioTherapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0.07% more ownership
Funds ownership: 0.5% → 0.57% (+0.07%)
4% less capital invested
Capital invested by funds: $4.63M → $4.46M (-$174K)
3% less funds holding
Funds holding: 36 → 35 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
39% less call options, than puts
Call options by funds: $28K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$944K |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$228K |
| 3 |
Renaissance Technologies
New York
|
+$208K |
| 4 |
SG Americas Securities
New York
|
+$148K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$313K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$215K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$108K |
| 4 |
Morgan Stanley
New York
|
-$51K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$47.7K |
PLX Hedge Fund Activity: Q1 2018 in Review
35 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2018, worth a combined $4.46M — down 3.8% from $4.63M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PLX and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Opaleye Management, adding an estimated $944K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $313K sold.
- 35 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2018, down from 36 in Q4 2017.
- Funds reported $4.46M of Protalix BioTherapeutics stock for Q1 2018, down 3.8% quarter-over-quarter.
- 6 funds opened new Protalix BioTherapeutics positions in Q1 2018 and 7 closed out, a net change of -1 holder.
- The largest Protalix BioTherapeutics buyer in Q1 2018 was Opaleye Management, an estimated $944K added.
- The largest Protalix BioTherapeutics seller in Q1 2018 was Highbridge Capital Management, an estimated $313K sold.
Based on aggregated 13F filings for Q1 2018.